R&D Partner Content 5th Gene Therapy for Ophthalmic Disorders Summit Ophthalmic drug developers are unlocking the full potential of gene therapy.
Partner Content Partner Content Exclusive interview with ForwardVue Pharma released for Opht... Exclusive interview with ForwardVue Pharma
Partner Content Partner Content Ophthalmic Drug Delivery Development - Trials and Tribulatio... Ophthalmic Drug Delivery Development Workshop
Partner Content Partner Content Novel Platforms in Ocular Drug Delivery workshop discussed a... Novel Platforms in Ocular Drug Delivery workshop
Partner Content Partner Content Aerie Pharmaceuticals interview released for Ophthalmic Drug... Ophthalmic Drugs
News Legal win leads Amgen to at-risk launch of Eylea biosimilar Amgen has chalked up a victory in a patent infringement lawsuit with Regeneron over blockbuster ophthalmic drug Eylea and decided to launch its biosimilar in the US – even though the legal
Sales & Marketing Sponsored Global reach, personal touch: Mastering customer engagement ... In today's interconnected pharma market, the ability to scale engagement across borders is essential for survival and growth.